

DR TRUNG QUANG KY (Orcid ID : 0000-0002-5564-7552)

Article type : Original Article

**Title: Oropharyngeal Candidiasis Outcomes in Renal Transplant Recipients Receiving Nystatin Versus  
No Antifungal Prophylaxis**

***Running Head: Thrush in Renal Transplant Recipients***

Trung Q. Ky, PharmD

Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan

ORCID: <https://orcid.org/0000-0002-5564-7552>

Address: 1111 E Catherine St, Ann Arbor MI, 48109

Jeong M. Park, MS, PharmD

College of Pharmacy, University of Michigan and Department of Pharmacy Services, Michigan Medicine,  
Ann Arbor, Michigan

ORCID: <https://orcid.org/0000-0002-7961-494X>

Katie A. McMurry, PharmD

Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan

ORCID: <https://orcid.org/0000-0003-2239-6651>

Sarah M. Tischer, PharmD

Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan

ORCID: <https://orcid.org/0000-0002-3179-948X>

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/TID.13559](https://doi.org/10.1111/TID.13559)

This article is protected by copyright. All rights reserved

Linda J. Fitzgerald, PharmD

Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan

ORCID: <https://orcid.org/0000-0001-8972-5531>

Laura Cotiguala, PharmD

Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan

ORCID: <https://orcid.org/0000-0002-5081-4649>

Address: 1111 E Catherine St, Ann Arbor MI, 48109

and

Trung Q. Ky

Email: [Tky@med.umich.edu](mailto:Tky@med.umich.edu)

Telephone: (734) 764-6990 | Fax: (734) 615-2314

Abstract (max 250): 246 | Text (max 3,500): 2,544 (no references), 3,051 (with references)

Tables: 3 | Figures: 1

**Authors Initials:** Ky TQ, Park JM, McMurry KA, Tischer SM, Fitzgerald LJ, Cotiguala L

**Manuscript Title:** Oropharyngeal Candidiasis Outcomes in Renal Transplant Recipients Receiving Nystatin Versus No Antifungal Prophylaxis

**Journal Title:** Transplant Infectious Disease

**Abstract:**

**Objective:** To compare the incidence of oropharyngeal candidiasis (OC), or thrush, in renal transplant recipients receiving nystatin versus no antifungal prophylaxis.

**Methods:** This was a single-center, retrospective, noninferiority study of adult renal transplant recipients (RTRs) who received nystatin for 30 days for OC prophylaxis (nystatin group) or no antifungal prophylaxis therapy (No PPX group). The primary outcome was the incidence of OC within three months post-transplant. Secondary outcomes included time to OC occurrence and severity of OC. The prespecified noninferiority margin was 10%.

**Results:** The incidence of OC within three months post-transplant among 257 RTRs was 7.8% (10/128) in the No PPX group and 4.7% (6/129) RTRs in the nystatin group, a risk difference of 3.2% (95% CI, -2.7% to 9.1%, noninferiority  $p=0.04$ ). The median time to OC was 7.5 days (IQR 6.3 - 34.3 days) in the nystatin group and 9.5 days (IQR 5.3 - 30.5 days) in the No PPX group ( $p=0.64$ ). Esophageal candidiasis was observed in 10% (1/10) of RTRs with OC in the No PPX group compared to 16.7% (1/6) RTRs in the nystatin group ( $p=1.00$ ). All RTRs with OC achieved symptom resolution with fluconazole and/or nystatin. Two patients in the No PPX group required readmission for decreased oral intake, and OC was diagnosed and treated during their hospital day.

**Conclusions:** In this retrospective study of adult RTRs, the absence of antifungal prophylaxis demonstrated noninferiority to 30-day nystatin prophylaxis at reducing the incidence of OC within three months of transplant. OC prophylaxis may not be warranted after renal transplant.

**Keywords:** oropharyngeal candidiasis; thrush, nystatin; antifungal prophylaxis; renal transplant; kidney transplant; esophageal candidiasis

**Corresponding Authors:**

**Trung Q. Ky**, Address: 1111 E Catherine St, Ann Arbor MI, 48109

**Laura Cotiguala**, Address: 1111 E Catherine St, Ann Arbor MI, 48109

## 1. Introduction

Oropharyngeal candidiasis, or OC, is a fungal infection associated with immunosuppression among solid organ transplant recipients.<sup>1-6</sup> OC presents as soft yellowish-white plaques or diffuse erythematous patches on the oral mucosa, which can cause patients to experience a cottony feeling in the mouth, altered taste and sense of smell, odynophagia, and dysphagia.<sup>4</sup> OC development can predispose patients to more severe manifestations such as esophageal candidiasis and disseminated *Candida* infections.<sup>7</sup>

The incidence of OC among renal transplant recipients (RTRs) is variable. While early reports observed rates of up to 50% within three months post-transplant in RTRs not receiving prophylaxis, more recent studies reported rates below 10% in RTRs receiving modern immunosuppression.<sup>1-3,5-8</sup> This decline may be attributed to improved surgical techniques and immunosuppressive regimens which have reduced peri-transplant complications, need for broad-spectrum antibiotics, and length of hospital

stays.<sup>9</sup> While OC rates are low in contemporary studies, there is limited evidence evaluating the risk of developing OC among RTRs in the absence of antifungal prophylaxis.

The 2009 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines recommend pharmacological prophylaxis against oral and esophageal *Candida* with clotrimazole lozenges, nystatin, or fluconazole for 1 to 3 months after renal transplant.<sup>10</sup> However, this recommendation is based on low quality evidence, and these antifungal agents carry clinical challenges. As a class, azoles like fluconazole and clotrimazole inhibit CYP3A4 in the liver and gut, through which immunosuppressants like calcineurin inhibitors (CNI) are metabolized.<sup>1,11,12</sup> Azole initiation may lead to supratherapeutic CNI trough levels which increases the renal toxicity risk to the allograft, while the discontinuation of azoles could result in subtherapeutic levels and potentially cause allograft rejection.<sup>1,11</sup>

Unlike azoles, nystatin does not inhibit CYP3A4, and thus, is favorable from an interaction profile perspective. However, due to its unpalatable taste, complex administration (i.e., swish and swallow), four times daily dosing, and the need to avoid eating and drinking after administration, patients have reported poor medication adherence to nystatin.<sup>8</sup> Several observational studies indicate that barriers to adherence and poorer quality of life are influenced by the complexity of drug regimens and increased dosing frequency of medications, ultimately emphasizing the urgency to simplify post-transplant medication regimens.<sup>13-15</sup>

One strategy of simplification was demonstrated by Guerra and colleagues, who questioned the need for prolonged antifungal prophylaxis. This group compared nystatin administered until time of discharge (average of 5.7 days of therapy) versus 30 days after transplant and observed no significant difference in the rates of OC (7.1% vs 0%,  $p=0.08$ ).<sup>6</sup> Although this study challenges commonly used strategies among RTRs that employ 1-3 months of antifungal prophylaxis, there is limited literature addressing the risk of developing OC in RTRs without pharmacologic prophylaxis in the modern era of immunosuppression and surgical advancements. Thus, our study investigated whether the omission of antifungal prophylaxis is associated with a clinically acceptable risk of OC development in RTRs. Our objective was to compare the incidence of OC in renal transplant recipients receiving nystatin versus no antifungal prophylaxis.

## **2. Methods**

### **2.1. Study Design, Population, and Immunosuppression**

This single-center, retrospective, noninferiority study was approved by the institutional review board at the University of Michigan. Electronic medical records were screened to identify adult RTRs transplanted between February 1, 2018 and December 31, 2019 at the University of Michigan Transplant Center. Patients transplanted before the nystatin shortage in December 2018 were universally administered nystatin prophylaxis, and patients transplanted after February 14, 2019 universally received no OC prophylaxis. As a result, we were able to screen patients for study inclusion by transplant date. Thus, eligible patients were divided into the nystatin group (transplanted between February 1, 2018 to November 30, 2018) and the no prophylaxis (No PPX) group (February 14, 2019 to December 31, 2019). Across the two study periods, immunosuppression regimens were the same with the exception of a change in rabbit anti-thymocyte globulin (rATG) induction to living unrelated renal transplants (LURT). All LURT were administered rATG induction during the entire study period except from April 1, 2018 to March 31, 2019, during which the use of rATG was limited to high immunologic risk patients only due to a cost savings initiative.

Patients were excluded if they received systemic antifungal treatment for any indication other than OC, used an alternative antifungal agent for OC prophylaxis (e.g., fluconazole), had less than three months of data after transplant due to death or lost to follow-up, had human immunodeficiency virus, received multi-organ transplants, or discharged on an immunosuppression other than tacrolimus, mycophenolate, and prednisone. Inpatient and outpatient electronic medical records were reviewed for patient baseline characteristics, which included demographics, comorbid conditions, tobacco and inhaled corticosteroid use, etiology for end-stage renal disease, and any documented history of OC. Transplant demographics included the surgery date, hospital admission and discharge dates, donor status, induction and maintenance immunosuppression therapy, and whether RTRs received nystatin or no antifungal prophylaxis therapy. Patients were asked to self-report adherence as part of their routine care. Notes from providers, nurses, social workers and pharmacists were reviewed to determine if a patient reported any medication non-adherence or whether non-adherence was a concern due to memory or cognitive concerns, psychiatric conditions, uncontrolled diabetes, low health literacy, limited social support, vision or hearing impairment, or language barriers.

The primary outcome was oropharyngeal candidiasis within three months post-kidney transplant. The secondary outcomes were the time to OC occurrence (measured from the transplant date to the OC diagnosis date) and the severity of the OC, as measured by the presence of esophageal candidiasis and any readmission where treatment for OC was initiated or continued. The pharmacologic treatment for OC and patient response to the treatment were collected in RTRs with OC.

## 2.2. OC Prophylaxis & Treatment

Prior to December 2018, nystatin 500,000-unit suspension four times daily for a total of 30 days was used per the institution protocol for OC prophylaxis in RTRs. Patients were instructed to orally swish nystatin for 15 to 30 seconds, swallow, and not to eat or drink for 15 minutes after taking nystatin. In response to a national shortage of nystatin starting December 3, 2018, the institution temporarily substituted fluconazole for antifungal prophylaxis therapy. Consequently, due to frequent supratherapeutic tacrolimus concentrations, the protocol was modified on February 14, 2019 to remove any antifungal agents for OC prophylaxis.

Diagnosis of OC was made if a provider documented plaque in the oral or esophageal mucosa on physical exam, clinically suspected OC based on signs and symptoms unexplained by other causes and prescribed antifungal treatment for OC with subsequent improvement. If there was appearance of esophageal candidiasis on esophagogastroduodenoscopy (EGD) exam and if symptoms improved on anti-fungal therapy, patients met criteria for clinical diagnosis of esophageal candidiasis. Selection of treatment agent was at the discretion of the provider.

## 2.3. Statistical Analysis

The study was designed to determine whether no antifungal prophylaxis would be noninferior to nystatin prophylaxis. To satisfy the criterion for noninferiority, the upper limit of a two-sided 95% confidence interval (CI) for the absolute difference between the two groups in the incidence of OC needed to be less than a predefined margin of 10%. The null hypothesis is that the risk difference is greater than or equal to 10%. A noninferiority p-value of less than 0.05 will support the claim that the risk difference is less than 10%. A sample size of 118 patients in each group was needed to rule out an absolute increase of 10% in the incidence of OC at 3 months in the No PPX group with 90% power on the basis of a 3% incidence of OC at 3 months in the nystatin group. Baseline characteristics between the two groups were compared using chi-squared or Fisher's exact tests for categorical data. Student t-tests or Mann-Whitney U were used for continuous data. A p-value less than 0.05 was considered statistically significant. All statistical analyses were conducted using Statistical Package for the Social Sciences (SPSS Version 26.0. Armonk, NY: IBM Corp).

## 3. **Results**

Out of 339 adult RTRs performed at the University of Michigan Transplant Center during the study period, a total of 257 RTRs were included in the analysis; 129 RTRs (50.2%) received nystatin prophylaxis and 128 RTRs (49.8%) did not (Figure 1). Overall the two groups were well matched in regard to baseline characteristics (Table 1). Significantly more patients in the No PPX group received rATG induction compared to the nystatin group (72.7% vs 54.3%,  $p=0.003$ ), which reflects the change in the center practice during the study period. Known risk factors for OC<sup>2</sup>, including prevalence of diabetes mellitus (DM), inhaled corticosteroids (ICS) use, and smoking were not significantly different between the two groups. No patients had documented candidiasis within 60 days prior to transplant.

Overall, 16 RTRs (6.2%) were clinically diagnosed with OC within three months post-transplant, with 10 in the No PPX group compared to six in the nystatin group (7.8% vs 4.7%,  $p = 0.316$ ) (Table 2). The absolute difference in the incidence of OC was estimated to be 3.2% (95% CI, -2.7% to 9.1%, noninferiority  $p=0.04$ ). The majority of OC cases (56.3%) were diagnosed within the first week after transplant. The median time to OC was not significantly different with 7.5 days (IQR 6.3 - 34.3 days) in the nystatin group and 9.5 days (IQR 5.3 - 30.5 days) in the No PPX group ( $p=0.64$ ).

One patient in each group had EGD confirmed esophageal candidiasis: 10.0% in the No PPX group vs. 16.7% in the nystatin group ( $p=1.00$ ). The patient in the No PPX group had invading fungal organisms found on biopsy. The patient in the nystatin group met diagnostic criteria for esophageal candidiasis based on EGD appearance and improvement after antifungal treatment although biopsy and cytology results did not show evidence of fungal infection. Both patients were treated with fluconazole. Despite the two cases of esophageal candidiasis, no patients subsequently developed graft rejection or required a dose reduction of their immunosuppression medications. All patients with OC achieved symptom resolution with fluconazole ( $n=10$ ), nystatin ( $n=3$ ), or both ( $n=3$ ) treatments, and none died due to OC or experienced rejection after treatment. Two patients in the No PPX group and one patient in the nystatin group required readmission due to the occurrence of OC.

A summary of the infected patients' characteristics is found on Table 3. None of the 16 patients who developed OC had a history of OC or smoking prior to transplant. Nine patients (56.3%) had DM and one patient (6.3%) used ICS before transplantation. Two OC cases were found among 40 diabetic patients in the nystatin group compared to seven among 51 diabetic patients in the No PPX group (5% vs 13.7%, respectively,  $p=0.289$ ). Of the RTRs with OC, 13 (81.3%) patients received induction therapy with rATG. Five patients (31.3%) were diagnosed during the index hospital stay with the longest duration of hospitalization being 14 days. For the three patients who were discharged more than one day after OC diagnosis, barriers to discharge included hiatal hernia, post-operative anemia requiring blood

transfusion, prolonged QTc interval, or delayed graft function; OC was not the primary reason for prolonged length of stay in any of these patients. Only 19.7% of those infected had documented adherence concerns (20.0% in the No PPX group vs. 16.7% in the nystatin group,  $p=1.00$ ). Among those who had medication adherence concerns, barriers documented in chart notes included stress, anxiety, depression, memory/cognitive problems, uncontrolled diabetes, and vision/hearing impairments.

#### 4. Discussion

In this study, the absence of antifungal prophylaxis provided noninferior three-month OC outcomes compared to a 30-day nystatin regimen in renal transplant recipients. This finding was corroborated by an OC incidence in the No PPX group that was within 10% of the nystatin group and was observed despite significantly more patients in the No PPX receiving rATG ( $p=0.003$ ). Rates of OC at three months were low at 6.2% (16/257) in this cohort of RTRs maintained on a modern maintenance immunosuppression regimen of tacrolimus, mycophenolate, and prednisone. This is consistent with a similar single-center, retrospective study of adult RTRs, which found only 3 of 84 (3.6%) total OC cases in patients receiving nystatin for 30 days or only up until discharge.<sup>6</sup> Contrary to the 2009 KDIGO guidelines, this study found the risk of withdrawing antifungal prophylaxis in this patient population to be clinically acceptable.<sup>10</sup> It is important to note that KDIGO's recommendation for prophylaxis is based on studies from past decades, and thus this study complements the current body of literature surrounding the indication for OC prophylaxis in renal transplant patients on contemporary immunosuppression.<sup>10</sup>

A strength of this study is the design structured around the nystatin shortage, which allowed for a quasi-experimental design. Importantly, baseline characteristics between groups were similar, including usage of inhaled corticosteroids, history of diabetes, and history of candidiasis. Maintenance immunosuppression regimen was the same between groups. Notably, our institution temporarily stopped administering rATG induction to low immunologic risk LURT from April 1, 2018 to March 31, 2019, which resulted in 17 patients in the nystatin group to not receive rATG. In spite of this protocol change that drove more patients in the No PPX versus nystatin group to receive lymphocyte depleting induction, OC incidence was not significantly different between groups.

After solid organ transplant, patients are at greatest risk of developing OC within the first month, but OC can also present many months later.<sup>16</sup> In this study, the majority of affected patients developed OC within one month, with half the patients diagnosed within one week of transplant. The early onset of



OC in some patients raises suspicion that OC was present prior to transplant, undiagnosed, and left untreated. While it is plausible that RTRs are likely colonized with oral *Candida*<sup>3,17</sup>, the prevalence of colonization in the RTRs of this study could not be confirmed as oral *Candida* cultures were not routinely obtained at time of transplant.

Established risk factors for OC include, but are not limited to, diabetes and smoking.<sup>2</sup> All patients who developed OC indicated having never smoked prior to transplant, and thus, this study cannot confirm smoking status as a risk factor. However, diabetes was a comorbid condition found in more than half (56.3%) of the RTRs who developed OC. One patient who was readmitted for OC was also found to have uncontrolled diabetes. Among patients who had a history of diabetes, there were a proportionately greater amount of OC cases in the No PPX group compared to the nystatin group, though the difference was not statistically significant ( $p=0.29$ ). Our study was not powered to evaluate the impact of withholding OC prophylaxis in higher-risk sub-populations, and further investigation of prophylaxis strategies in patients actively smoking or with poor glycemic control may be warranted.

Esophageal candidiasis in renal transplant patients can sometimes be preceded by oral OC.<sup>7</sup> This study showed similar incidences of esophageal candidiasis in the No PPX group compared to the nystatin group (10% vs. 16.7%,  $p=1.00$ ). Although there were two cases of esophageal candidiasis, graft rejection or dose reduction of immunosuppression medications was not observed. There was no observed association between OC and increased risk of subsequent rejection, and notably, all OC improved without needing to lower maintenance immunosuppression. Furthermore, all patients achieved symptom resolution with standard OC treatments and did not require a prolonged hospitalization due to OC. These findings suggest that the complications associated with OC may be acceptable without universal prophylaxis.

There are several limitations to this study. Given the retrospective, observational design of this single-center study, the attributable effect of nystatin cannot be fully determined. A larger randomized, controlled trial, where oral swabs are used to screen for candida colonization prior to transplant would be informative to determine the role of antifungal prophylaxis in colonized RTRs. Since our institution does not have a routine or formal screening process for OC in renal transplant recipients, some of the recorded cases relied on patients to self-report symptoms, which may have led to an underestimation of OC rates in both groups. The outcomes reflect RTRs who were managed by one immunosuppressive regimen strategy consisting of tacrolimus, mycophenolate, and prednisone. However, we expect that the difference in the incidence of OC among RTRs on a steroid-avoidance maintenance immunosuppressive regimen would be even smaller. The No PPX group was compared with only

nystatin; therefore, no inference can be made for other antifungal prophylaxis agents. Meanwhile, all patients were followed for only three months post-transplant, yet studies indicate possible later development of OC.<sup>16</sup> Finally, this study did not formally evaluate adherence to medication regimens or measure quality of life.<sup>3,9,16</sup>

To our knowledge, this is the first adequately powered retrospective study to demonstrate noninferiority of no antifungal prophylaxis compared to nystatin. The findings are similar to other studies that report low rates of OC and contributes to the body of evidence that challenges the absolute need for antifungal prophylaxis. Ultimately, this study has implications for renal transplant recipients that struggle with medication adherence and poorer quality of life due to regimen complexity, inconvenient dosing frequency, polypharmacy, or the unpalatable taste of nystatin. Given the low incidence of OC, questionable benefit of antifungal prophylaxis, and continual efforts to simplify post-transplant medication regimens, we advocate that the elimination of OC prophylaxis after renal transplant is possibly clinically acceptable, although these results need to be confirmed by a randomized controlled clinical trial. In the absence of OC prophylaxis, we recommend educating patients to report any signs and symptoms of OC and visually examining the oral cavity at routine follow-up visits.

#### **Acknowledgments/Funding**

None.

#### **Financial Disclosures**

No conflicts of interest to disclose.

#### **Authors Contributions**

| <b>Author</b>    | <b>Contributions</b>   |
|------------------|--|
| Trung Q. Ky      | <i>Concept/design, data collection, data analysis/interpretation, drafting article, critical revision of article</i> |
| Jeong M. Park    | <i>Concept/design, data collection, data analysis/interpretation, critical revision of article</i>                   |
| Katie A. McMurry | <i>Concept/design, data collection, critical revision of article</i>   |
| Sarah M. Tischer | <i>Data collection, critical revision of article</i>   |

|                     |  |
|---------------------|--|
| Linda J. Fitzgerald | <i>Data collection, critical revision of article</i>   |
| Laura Cotiguala     | <i>Concept/design, data collection, data analysis/interpretation, drafting article, critical revision of article</i> |

## References

1. Sikora MB, Truax C, Lee S, et al. Low-dose fluconazole prophylaxis in kidney transplant recipients receiving tacrolimus. *Clin Transplant*. 2012;26(5).
2. López-Pintor RM, Hernández G, de Arriba L, de Andrés A. Oral candidiasis in patients with renal transplants. *Med Oral Patol Oral Cir Bucal*. 2013;18(3).
3. Al-Mohaya MA, Darwazeh A, Al-Khudair W. Oral fungal colonization and oral candidiasis in renal transplant patients: The relationship to Miswak use. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2002;93(4):455-460.
4. Coronado-Castellote L, Jiménez-Soriano Y. Clinical and microbiological diagnosis of oral candidiasis. *J Clin Exp Dent*. 2013;5(5):279-286.
5. Owens NJ, Nightingale CH, Schweizer RT, Schauer PK, Dekker PT, Quintiliani R. Prophylaxis of oral candidiasis with clotrimazole troches. *Arch Intern Med*. 1984;144(2):290-293.
6. Guerra CM, Formica RN, Kulkarni S, Asch WS, Tichy EM. Duration of prophylaxis against fungal infection in kidney transplant recipients. *Prog Transplant*. 2015;25(4):311-315.
7. Gupta KL, Ghosh AK, Kochhar R, Jha V, Chakrabarti A, Sakhuja V. Esophageal candidiasis after renal transplantation: comparative study in patients on different immunosuppressive protocols. *Am J Gastroenterol*. 1994;89(7):1062–1065.
8. Gombert ME, Dubouchet L, Aulicino TM, Butt KMH. A Comparative Trial of Clotrimazole Troches and Oral Nystatin Suspension in Recipients of Renal Transplants: Use in Prophylaxis of Oropharyngeal Candidiasis. *JAMA J Am Med Assoc*. 1987;258(18):2553-2555.
9. Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: Current epidemiology and associated risk factors. *Clin Transplant*. 2006;20(4):401-409.
10. Chapman JR. The KDIGO clinical practice guidelines for the care of kidney transplant recipients. *Transplantation*. 2010;89(6):644-645.
11. Manez R, Martin M, Raman D, et al. Fluconazole therapy in transplant recipients receiving FK506. *Transplantation*. 1994;57(10):1521-1523.

12. Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. *Clin Transplant*. 2001;15(2):95-99.
13. Chisholm-Burns MA, Spivey CA, Graff Zivin J, Lee JK, Sredzinski E, Tolley EA. Improving outcomes of renal transplant recipients with behavioral adherence contracts: A randomized controlled trial. *Am J Transplant*. 2013;13(9):2364-2373.
14. Chisholm MA. Identification of medication-adherence barriers and strategies to increase adherence in recipients of renal transplants. *Manag Care Interface* 2004; 17: 44.
15. Morales JM, Varo E, Lázaro P. Immunosuppressant treatment adherence, barriers to adherence and quality of life in renal and liver transplant recipients in Spain. *Clin Transplant*. 2012;26(2):369-376.
16. Dongari-Bagtzoglou A, Dwivedi P, Ioannidou E, Shaqman M, Hull D, Burleson J. Oral Candida infection and colonization in solid organ transplant recipients. *Oral Microbiol Immunol*. 2009;24(3):249-254.
17. Güleç AT, Demirbilek M, Seçkin D, et al. Superficial fungal infections in 102 renal transplant recipients: a case-control study. *J Am Acad Dermatol*. 2003;49(2):187-192.

**Table 1. Baseline Characteristics**

|   | Nystatin (n=129) | No PPX (n=128) | P-value |
|---|------------------|----------------|---------|
| Mean length of stay, days (SD)              | 4.4 (2.3)        | 4.5 (2.3)      | 0.951   |
| Mean age, years (SD)                        | 52.1 (13.6)      | 53.5 (13.8)    | 0.445   |
| Male, n (%)                                 | 76 (58.9)        | 87 (68.0)      | 0.155   |
| Race, n (%)                                 |                  |                | 0.650   |
| White                                       | 99 (76.7)        | 93 (72.7)      |         |
| Black                                       | 17 (13.2)        | 17 (13.3)      |         |
| Hispanic                                    | 8 (6.2)          | 11 (8.6)       |         |
| Asian                                       | 4 (3.1)          | 3 (2.3)        |         |
| Other                                       | 1 (0.8)          | 4 (3.1)        |         |
| Transplant etiology, n (%)                  |                  |                | 0.216   |
| Glomerulonephritis                          | 11 (8.5)         | 8 (6.3)        |         |
| Diabetes                                    | 31 (24.0)        | 42 (32.8)      |         |
| Hypertension                                | 11 (8.5)         | 20 (15.6)      |         |
| Polycystic kidney disease                   | 16 (12.4)        | 14 (10.9)      |         |
| IgA-mediated nephritis                      | 14 (10.9)        | 7 (5.5)        |         |
| Focal segmental glomerulosclerosis          | 5 (3.9)          | 5 (3.9)        |         |
| Other                                       | 41 (31.8)        | 32 (25)        |         |
| Mean peak Panel Reactive Antibodies, % (SD) |                  |                |         |
| Class I                                     | 13.0 (26.2)      | 8.6 (21.4)     | 0.149   |
| Class II                                    | 9.9 (23.6)       | 5.8 (18.5)     | 0.125   |
| Donor, n (%)                                |                  |                | 0.982   |
| Deceased                                    | 74 (57.4)        | 75 (58.6)      |         |
| Living, related                             | 13 (10.1)        | 13 (10.2)      |         |
| Living, unrelated                           | 42 (32.6)        | 40 (31.3)      |         |
| Dialysis prior to transplant, n (%)         | 99 (76.7)        | 90 (70.3)      | 0.260   |
| Median dialysis time, years (IQR)           | 2.8 (1.3-4.7)    | 3.0 (1.0-4.9)  | 0.704   |
| Induction, n (%)                            |                  |                | 0.003   |
| Antithymocyte globulin                      | 70 (54.3)        | 93 (72.7)      |         |
| Basiliximab                                 | 2 (1.6)          | 0              |         |

|                                   |           |           |       |
|-----------------------------------|-----------|-----------|-------|
| None                              | 57 (44.2) | 35 (27.3) |       |
| History of candidiasis, n (%)     | 4 (3.1)   | 0         | 0.122 |
| Diabetes, n (%)                   | 40 (31.0) | 51 (39.8) | 0.153 |
| Inhaled corticosteroid use, n (%) | 4 (3.1)   | 5 (3.9)   | 1.00  |
| Smoker, n (%)                     |           |           | 0.866 |
| Current                           | 5 (3.9)   | 3 (2.3)   |       |
| Former                            | 48 (37.2) | 49 (38.3) |       |
| Never                             | 76 (58.9) | 76 (59.4) |       |
| Rejection, n (%)                  | 7 (5.4)   | 4 (3.1)   | 0.540 |

IQR: interquartile range, SD: standard deviation

**Table 2. Primary and Secondary Outcomes**

|                                      | Nystatin (n=129) | No PPX (n=128) | P-value |
|--------------------------------------|------------------|----------------|---------|
| Thrush incidence, n (%)              | 6 (4.7)          | 10 (7.8)       | 0.316   |
| Median time to diagnosis, days (IQR) | 7.5 (6.3-34.3)   | 9.5 (5.3-30.5) | 0.635   |
| Esophageal candidiasis, n (%)        | 1 (16.7)         | 1 (10)         | 1.000   |
| Readmission due to thrush, n (%)     | 1 (16.7)         | 2 (10)         | 1.000   |
| Diabetes history, n (%)              | 40 (31)          | 51 (39.8)      | 0.153   |
| Thrush incidence, n (%)              | 2 (5)            | 7 (13.7)       | 0.289   |

IQR: interquartile range

Author Manuscript

**Table 3. All Thrush Cases**

| Group    | Age | Sex | LOS | Race | Cause                | Donor | DM | ICS | Dialysis (years) | Induction | Rejection | Time since transplant (days) | Symptoms  | Esophageal Candidiasis | Treatment                | Readmission   | Adherence concerns |
|----------|-----|-----|-----|------|----------------------|-------|----|-----|------------------|-----------|-----------|------------------------------|---|------------------------|--------------------------|---------------|--------------------|
| No PPX   | 57  | F   | 4   | H    | PCKD                 | DDKT  | Y  | N   | 5.7              | Y         | N         | 12                           | Epigastric pain   | Y                      | Fluconazole              | N             | No                 |
| No PPX   | 64  | F   | 11  | W    | DM                   | DDKT  | Y  | N   | 2.1              | Y         | N         | 5                            | Dysphagia, Odynophagia  | N                      | Fluconazole              | N             | No                 |
| No PPX   | 59  | M   | 5   | B    | DM                   | DDKT  | Y  | N   | 6                | Y         | N         | 36                           | Odynophagia, heartburn  | N                      | Fluconazole              | Y, persistent | Yes                |
| No PPX   | 70  | M   | 6   | W    | DM                   | LUKT  | Y  | N   | 0.83             | Y         | N         | 3                            | Dysphagia, Odynophagia  | N                      | Nystatin                 | N             | No                 |
| No PPX   | 64  | F   | 6   | W    | Reflux nephropathy   | DDKT  | N  | N   | N/A              | Y         | N         | 14                           | Dry mouth; states feels like she has a film in her mouth; states brushes teeth several times throughout day | N                      | Fluconazole and Nystatin | N, thrush x2  | No                 |
| No PPX   | 28  | F   | 4   | H    | Lupus                | LUKT  | N  | N   | 0.70             | Y         | N         | 6                            | Odynophagia   | N                      | Nystatin                 | N             | No                 |
| No PPX   | 60  | F   | 6   | B    | DM                   | DDKT  | Y  | N   | 6.67             | Y         | N         | 7                            | Dysphagia, Odynophagia, epigastric pain complicated by pancreatitis   | N                      | Fluconazole and Nystatin | Y             | No                 |
| No PPX   | 35  | M   | 7   | H    | DM                   | DDKT  | Y  | N   | 6.48             | Y         | N         | 4                            | Dysphagia, Odynophagia, heartburn   | N                      | Fluconazole              | N             | No                 |
| No PPX   | 60  | F   | 7   | W    | DM                   | DDKT  | Y  | N   | 4.52             | Y         | N         | 38                           | Dysphagia, Odynophagia  | N                      | Fluconazole and Nystatin | N             | No                 |
| No PPX   | 64  | M   | 4   | W    | Hepatorenal syndrome | DDKT  | N  | N   | 3.64             | Y         | N         | 57                           | Not documented  | N                      | Nystatin                 | N             | No                 |
| Nystatin | 55  | M   | 4   | W    | Unknown              | DDKT  | N  | N   | 2.42             | N         | N         | 43                           | Oral pain   | N                      | Fluconazole              | N             | No                 |
| Nystatin | 70  | F   | 14  | W    | Alport's syndrome    | DDKT  | N  | Y   | 0.59             | Y         | N         | 82                           | Dysphagia   | N                      | Fluconazole              | N, recurrent  | No                 |
| Nystatin | 34  | F   | 8   | W    | Alport's syndrome    | DDKT  | N  | N   | N/A              | Y         | N         | 8                            | Not documented  | N                      | Fluconazole              | N             | No                 |



|          |    |   |   |   |                       |      |   |   |      |   |               |   |   |   |             |   |    |
|----------|----|---|---|---|-----------------------|------|---|---|------|---|---------------|---|---|---|-------------|---|----|
| Nystatin | 61 | F | 3 | W | DM                    | DDKT | Y | N | 6.05 | N | TCMR,<br>rATG | 7 | Dysphagia, severe<br>esophagitis and<br>gastroparesis | N | Fluconazole | N, for<br>rejection<br>then thrush<br>found | No |
| Nystatin | 58 | F | 7 | W | Nephrotic<br>syndrome | DDKT | Y | N | 6.43 | N | N             | 6 | Dysphagia   | Y | Fluconazole | Y   | No |
| Nystatin | 64 | F | 5 | W | PCKD                  | DDKT | N | N | 1.35 | Y | N             | 5 | Presumed by MD,<br>Not documented                     | N | Fluconazole | N   | No |

B: Black, DDKT: deceased donor kidney transplant, DM: diabetes mellitus, F: female, H: Hispanic, ICS: inhaled corticosteroid, LOS: length of stay, LUKT: living unrelated kidney transplant, M: male, N: no, N/A: not applicable,

PCKD: polycystic kidney disease, rATG: rabbit anti-thymocyte globulin, TCMR: t-cell mediated rejection, W: White, Y: yes

Author Manuscript

Figure 1. Flow chart outlining inclusion and exclusion criteria and different groups.

